Abnormal production of the tumor necrosis factor inhibitor etanercept and clinical efficacy of tumor in a patient with PAPA syndrome

Elisabetta Cortis, Fabrizio De Benedetti, Antonella Insalaco, Stefania Cioschi, Flaminia Muratori, Leila E. D'Urbano, Alberto G. Ugazio

Research output: Contribution to journalArticle

Abstract

We report a family with pyogenic sterile arthritis, pyoderna and acne syndrome (PAPA). The proband presented several episodes of sterile pyogenic arthritis and became unresponsive to glucocorticoids. After treatment with the tumor necrosis factor inhibitor etanercept, the disease underwent rapid and sustained clinical remission. Production of tumor necrosis factor-α by mononuclear cells of the proband and of the affected relatives was abnormally elevated.

Original languageEnglish
Pages (from-to)851-855
Number of pages5
JournalJournal of Pediatrics
Volume145
Issue number6
DOIs
Publication statusPublished - Dec 2004

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Abnormal production of the tumor necrosis factor inhibitor etanercept and clinical efficacy of tumor in a patient with PAPA syndrome'. Together they form a unique fingerprint.

  • Cite this